The Firm recently represented AGA Medical Holdings, Inc. in its initial public offering. The offering of 13,750,000 shares of common stock raised approximately $200 million and included the issuance and sale of 6,509,000 shares by AGA Medical Holdings, Inc. and the sale of 7,241,000 shares by affiliates of Franck L. Gougeon, one of the controlling stockholders of the company. AGA Medical Holdings, Inc. used the net proceeds of the offering it received primarily to repay outstanding debt.
The shares of AGA Medical Holdings, Inc. are listed on the Nasdaq Global Select Market under the ticker symbol "AGAM".
Merrill Lynch, Pierce, Fenner & Smith Incorporated, Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Leerink Swann LLC, Wells Fargo Securities, LLC and Natixis Bleichroeder Inc. were the underwriters for the offering.
AGA Medical Holdings, Inc. is a leading innovator and manufacturer of medical devices for the treatment of structural heart defects and vascular diseases. It is the only manufacturer with occlusion devices approved to close seven different structural heart defects, with leading market positions in the United States and Europe.
The Simpson Thacher team for the transaction included Ken Wallach, John Tehan, Grenfel S. Calheiros, S.J. Gagliardi, Adam Booken and Jim Doyle (Capital Markets), Ivan Rothman and Noah Richmond (IP), Jamin Koslowe (Executive Compensation and Employee Benefits), and Jon Cantor, Jason Vollbracht and Andrew Purcell (Tax). Paralegal Kathryn Reusi also provided valuable assistance.